COVID-19 vaccine

Freshfields Bolsters Life Sciences Practice With Addition of Partners Kristen Riemenschneider and Vinita Kailasanath

Monday, October 25, 2021 - 1:00pm

Freshfields Bruckhaus Deringer LLP has further strengthened its preeminent life sciences and technology offering with the addition of two partners.

Key Points: 
  • Freshfields Bruckhaus Deringer LLP has further strengthened its preeminent life sciences and technology offering with the addition of two partners.
  • I am thrilled to welcome Kristen and Vinita to our growing, cutting-edge life sciences practice, said Mr. Golden, who joined the firm in May 2021.
  • Kristen and Vinita are a powerhouse team who strengthen our exemplary bench of life sciences attorneys globally, said Ms. Bethlehem.
  • Ms. Riemenschneider said, Freshfields has an exceptional cross-border practice and depth of experience in the life sciences sector.

Mortality study reinforces safety of COVID-19 vaccinations

Friday, October 22, 2021 - 6:00pm

The study looked at only non-COVID-19-related deaths to avoid masking any safety concerns regarding COVID-19 vaccine-related death with the protective effects of COVID-19 vaccine.

Key Points: 
  • The study looked at only non-COVID-19-related deaths to avoid masking any safety concerns regarding COVID-19 vaccine-related death with the protective effects of COVID-19 vaccine.
  • The study population included members of 7 Vaccine Safety Datalink sites: Kaiser Permanente Southern California, Kaiser Permanente Northern California, Kaiser Permanente Colorado, Kaiser Permanente Northwest, Kaiser Permanente Washington, HealthPartners in Minnesota, and Marshfield Clinic in Wisconsin.
  • This study was funded through the Vaccine Safety Datalink under a contract from the Centers for Disease Control and Prevention.
  • Each participating site regularly prepares standardized data files containing information on demographics, health plan enrollment, births, vaccinations, mortality, and health care utilization.

Emergency Physicians: We Must Address Vaccine Hesitancy, Correct Misinformation to End Pandemic

Friday, October 22, 2021 - 3:09pm

SAN ANTONIO, Oct. 22, 2021 /PRNewswire/ -- Widespread misinformation about COVID-19 vaccines and treatments fuels vaccine hesitancy and stands in the way of efforts to end the pandemic, according to doctors with the American College of Emergency Physicians (ACEP).

Key Points: 
  • SAN ANTONIO, Oct. 22, 2021 /PRNewswire/ -- Widespread misinformation about COVID-19 vaccines and treatments fuels vaccine hesitancy and stands in the way of efforts to end the pandemic, according to doctors with the American College of Emergency Physicians (ACEP).
  • A growing number of my patients want the vaccine, but they hesitate because they are surrounded by misinformation.
  • Others face practical barriers, like limited internet access, or lack of transportation to a vaccination site.
  • Getting vaccinated helps everyone protect themselves and others who are more vulnerable because they are too young or too sick for the vaccine.

Walgreens Now Offering Moderna and Johnson & Johnson COVID-19 Vaccine Booster Shots Nationwide

Friday, October 22, 2021 - 2:29pm

Walgreens announced today that eligible individuals can now receive Moderna and Johnson & Johnson (J&J) COVID-19 vaccine booster shots in stores nationwide following the Food and Drug Administration (FDA) Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention (CDC).

Key Points: 
  • Walgreens announced today that eligible individuals can now receive Moderna and Johnson & Johnson (J&J) COVID-19 vaccine booster shots in stores nationwide following the Food and Drug Administration (FDA) Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention (CDC).
  • View the full release here: https://www.businesswire.com/news/home/20211022005293/en/
    New CDC guidance recommends Moderna and J&J COVID-19 vaccine booster shots.
  • Moderna COVID-19 Booster Eligibility: Eligibility requirements for Moderna and Pfizer-BioTech booster doses are the same.
  • Individuals must wait at least six months after they complete their initial mRNA COVID-19 primary vaccine series to receive their booster dose.

IAA, Inc. Announces Acquisition of SYNETIQ Ltd.

Friday, October 22, 2021 - 11:45am

IAA, Inc. will acquire the stock of SYNETIQ through its indirect wholly owned subsidiary IAA International Holdings Limited.

Key Points: 
  • IAA, Inc. will acquire the stock of SYNETIQ through its indirect wholly owned subsidiary IAA International Holdings Limited.
  • John Kett, Chief Executive Officer and President of IAA, said, We are very excited about the acquisition of SYNETIQ.
  • IAA and SYNETIQ will continue to operate independently in the market until clearance of the transaction is obtained from the CMA.
  • In this release, such forward-looking statements include statements regarding the expected timing and associated benefits with respect to the acquisition of SYNETIQ Ltd.

On Pfizer CEO Albert Bourla’s Birthday, Medical Students and Activists from Health GAP, Rise and Resist, CPD Action and More Protest at His Home to Demand Equitable Global Access to COVID-19 Vaccines

Thursday, October 21, 2021 - 10:12pm

This is the third time activists have demanded global access to COVID-19 vaccines at the doorsteps of key duty-bearers.

Key Points: 
  • This is the third time activists have demanded global access to COVID-19 vaccines at the doorsteps of key duty-bearers.
  • Vinay Krishnan, National Field Organizer, CPD Action , said: Today is Albert Bourlas birthday, so we decided to pay him a house visit.
  • Of all the lives lost because Pfizer, Moderna, and yes, President Biden, refuse to take action to end vaccine apartheid.
  • We need to put people over profits and take global action to end this global crisis.

ABT/CDC STUDY FINDS CHILDREN AND ADULTS HAVE SIMILAR CORONAVIRUS INFECTION RATES

Thursday, October 21, 2021 - 3:00pm

The results are based on the Coronavirus Household Evaluation and Respiratory Testing (C-HEaRT) study, which Abt Associates manages for the Centers for Disease Control and Prevention (CDC).

Key Points: 
  • The results are based on the Coronavirus Household Evaluation and Respiratory Testing (C-HEaRT) study, which Abt Associates manages for the Centers for Disease Control and Prevention (CDC).
  • The C-HEaRT study followed 310 households with one or more children aged 0 to 17 years in New York City and selected counties in Utah.
  • The study monitored SARS-CoV-2 from September 2020 through August 2021, though the article covered data only through mid-April 2021, the most active infection period before the Delta variant emerged in the U.S.
  • Duque added that the study proved at-home weekly testing of children is feasible since many families enjoyed participating in the study.

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

Thursday, October 21, 2021 - 2:00pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.
  • BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles.
  • Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.
  • Ligands OmniAb technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies.

The GEO Group Enters Into New Lease Agreement With the State of New Mexico at the Guadalupe County Correctional Facility

Thursday, October 21, 2021 - 11:55am

The GEO Group (NYSE: GEO) (GEO) announced today that it has entered into a new two-year lease agreement, with successive two-year renewal option periods through October 31, 2041, with the State of New Mexico at the company-owned, 600-bed Guadalupe County Correctional Facility.

Key Points: 
  • The GEO Group (NYSE: GEO) (GEO) announced today that it has entered into a new two-year lease agreement, with successive two-year renewal option periods through October 31, 2041, with the State of New Mexico at the company-owned, 600-bed Guadalupe County Correctional Facility.
  • GEO has operated the Guadalupe County Correctional Facility under a management contract with New Mexico and will transition facility operations to the New Mexico Corrections Department when the new lease agreement commences on November 1, 2021.
  • GEO will retain responsibility for facility maintenance throughout the term of the lease.
  • For the first six months ended June 30, 2021, the Guadalupe County Correctional Facility generated operating revenue of approximately $4 million.

Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources

Wednesday, October 20, 2021 - 5:01am

The unjust reality, however, is that low-income countries have had to wait for everything from personal protective equipment to vaccines.

Key Points: 
  • The unjust reality, however, is that low-income countries have had to wait for everything from personal protective equipment to vaccines.
  • That is unacceptable," said Melinda French Gates, co-chair of the Gates Foundation.
  • We are pleased to work alongside these efforts to ensureaffordability and availability in lower-income countries," said Bill Gates, co-chair of the Gates Foundation.
  • Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and Melinda French Gates.